Care is required in epileptic patients receiving anticonvulsant therapy as it may lower the seizure threshold; and should be avoided in untreated epileptics. Elderly and debilitated patients may be more prone to its adverse effects. Administration at extremes of temperature may be hazardous since body temperature regulation is impaired by these agents. Regular eye examination are advisable for patients receiving long-term Fluphenazine therapy and avoidance of undue exposure to direct sunlight is recommended. Patients should remain supine for at least 30 minutes after parental administration, and blood pressure should be monitored.
Use in Pregnancy: Risk-benefit must be considered since jaundice and prolonged extra pyramidal effects have been reported in the neonates of mothers who receive some fluphenazine near terms. It is not recommended for use during pregnancy.
Use in Lactation: Risk-benefit must be considered since small amounts of some phenothiazine have been found in breast milk, possibly causing drowsiness and an increased risk of dystonias and tardive dyskinesia in the baby. Most phenothiazines increase prolactin secretion in the mother.